NFKB1 and Miyoshi myopathy: The combination of the anti IGF-1R antibody with AS602868 increased the cytotoxic effect in MM cell lines, suggesting that simultaneous targeting of IGF-1 signalling and the NF-κB pathway could be of therapeutic value in multiple myeloma.